Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
MEI Pharma (GB:0JW9)
LSE:0JW9
Holding GB:0JW9?
Track your performance easily
0JW9 Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.67 - $7.86
Previous Close$2.76
Volume250.00
Average Volume (3M)1.95K
Market Cap
$18.32M
Enterprise Value-$20.02M
Total Cash (Recent Filing)$38.34M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)1.0
Beta0.48
Next Earnings
Nov 07, 2024EPS EstimateN/A
Last Dividend Ex-Date
Nov 16, 2023Dividend YieldN/A
Share Statistics
EPS (TTM)2.67
Shares Outstanding6,662,857
10 Day Avg. Volume79
30 Day Avg. Volume1,954
Standard Deviation0.26
R-Squared0.01
Alpha-0.00221
Financial Highlights & Ratios
Price to Book (P/B)0.65
Price to Sales (P/S)0.28
Price to Cash Flow (P/CF)-0.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-0.31
Enterprise Value/Gross Profit-0.31
Enterprise Value/Ebitda-1.15
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering2
MEI Pharma News
PremiumCompany Announcements
MEI Pharma Explores Strategic Shifts, Leadership Changes
PremiumCompany Announcements
MEI Pharma Explores Strategic Options, Halts Drug Development
Options Prices
Currently, No data available
---
Ownership Overview
26.78% Insiders
6.97% Mutual Funds
0.11% Other Institutional Investors
61.81% Public Companies and
Individual Investors
0JW9 FAQ
What was MEI Pharma’s price range in the past 12 months?
MEI Pharma lowest share price was $2.67 and its highest was $7.86 in the past 12 months.
What is MEI Pharma’s market cap?
Currently, no data Available
When is MEI Pharma’s upcoming earnings report date?
MEI Pharma’s upcoming earnings report date is Nov 07, 2024 which is in 19 days.
How were MEI Pharma’s earnings last quarter?
MEI Pharma released its earnings results on Sep 19, 2024. The company reported -$2.76 earnings per share for the quarter, missing the consensus estimate of -$1.407 by -$1.353.
Is MEI Pharma overvalued?
According to Wall Street analysts MEI Pharma’s price is currently Overvalued.
Does MEI Pharma pay dividends?
MEI Pharma pays a Notavailable dividend of $1.75 which represents an annual dividend yield of N/A. See more information on MEI Pharma dividends here
What is MEI Pharma’s EPS estimate?
MEI Pharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MEI Pharma have?
MEI Pharma has 6,662,857 shares outstanding.
What happened to MEI Pharma’s price movement after its last earnings report?
MEI Pharma reported an EPS of -$2.76 in its last earnings report, missing expectations of -$1.407. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of MEI Pharma?
Among the largest hedge funds holding MEI Pharma’s share is Carlson Capital LP. It holds MEI Pharma’s shares valued at N/A.
---
MEI Pharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
― (―)
― (―)
Blogger Sentiment
Bullish
GB:0JW9 Sentiment 100%
Sector Average 70%
Sector Average 70%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-47.55%
12-Months-Change
Fundamentals
Return on Equity
61.68%
Trailing 12-Months
Asset Growth
-65.75%
Trailing 12-Months
Company Description
MEI Pharma
MEI Pharma, Inc. engages in the clinical development of therapies for cancer. Its drug candidates includes Pracinostat, an oral HDAC inhibitor that is being developed in combination with azacitidine for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Its pipeline also consists of ME-401, an oral PI3K delta inhibitor; Voruciclib, an oral CDK inhibitor; and ME-344, a mitochondrial inhibitor. The company was founded on December 1, 2000 and is headquartered in San Diego, CA.
---
0JW9 Earnings Call
Q4 2023
0:00 / 0:00
---
0JW9 Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Kintara Therapeutics
―
Evofem Biosciences
―
Aclaris Therapeutics
―
Crispr Therapeutics AG
―
MEI Pharma
―
---